Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Fortuna Mining Corp. Common Shares (FSM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Fortuna Mining Corp. Common Shares — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.06 (market cap $2.86B), while Fortuna Mining Corp. Common Shares trades at $10.42 (market cap $3.12B). The key difference: Dyne Therapeutics Inc. Common Stock and Fortuna Mining Corp. Common Shares are close in size by market cap, and Fortuna Mining Corp. Common Shares is trading nearer its 52-week high, Dyne Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Fortuna Mining Corp. Common Shares for 6 Days on average.
| DYN | FSM | |
|---|---|---|
Market Cap | $2.86B | $3.12B |
Volume | 3,341,579 | 2,648,950 |
Sector | Health | Basic Materials |
52-Week High | $26.78 | $13.66 |
52-Week Low | $14.60 | $7.84 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $2.18B | $2.74B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
Fortuna Mining (FSM) trades at $10.58, down 1.67% on the day, amid a bearish technical signal. The company reported strong 2025 results with $947M revenue and $287M net income, but recent quarters have missed EPS expectations. Analyst consensus is bullish with 4 buy ratings, while technical indicators show mixed signals with a bearish moving average trend but neutral oscillators.
FSM presents a value opportunity with low P/E of 8.89 and robust profitability margins, but faces risks from production volatility and execution of growth projects. The stock's near-term performance hinges on Q3 2026 earnings and progress toward its 500,000-ounce gold production target by 2028.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Fortuna Mining Corp. Common Shares
Fortuna Mining is a Canadian precious-metals mining company with operations in Latin America and West Africa. It produces gold and silver and conducts exploration activities in several countries.
Read more on FSM →
